Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 8/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458354 | 0.85 | HSD17B10 (0.52) | HSD17B10TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL57882 | 0.82 | TSHR (0.40) | HSD17B10TSHRCYP3A4ALDH1A1TDP1 | |
| SCHEMBL6800906 | 0.80 | TDP1 (0.38) | HSD17B10TSHRCYP3A4ALDH1A1TDP1 | |
| SCHEMBL7814797 | 0.79 | HSD17B10 (0.50) | HSD17B10TSHRCYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL1086344 | 0.78 | HSD17B10 (0.34) | HSD17B10TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL1028967 | 0.78 | TDP1 (0.50) | HSD17B10TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL456636 | 0.78 | PDK1 (0.41) | HSD17B10TSHRCYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL1028675 | 0.77 | GPR35 (0.47) | HSD17B10TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL5675005 | 0.77 | TDP1 (0.35) | HSD17B10TSHRCYP3A4ALDH1A1TDP1 | |
| SCHEMBL710076 | 0.77 | ALDH1A1 (0.47) | HSD17B10TSHRCYP3A4ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 780 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117720495-A | Preparation method of novel amide-containing coumarin derivative, antibacterial effect of composition and application of composition in aspect of promoting plant growth | 贵州工业职业技术学院 | 2024-03-19 | — | — | CN | claimed |
| CN-115583922-B | Fluorine-containing N- (3- (benzoxazol-2-yl) phenyl) amide compound and preparation method and application thereof | 黄山学院 | 2023-09-19 | — | — | CN | claimed |
| CN-116239591-A | (4R) -sulfonamido-L-prolinamide compound, preparation method, application and pharmaceutical composition thereof | 嘉兴学院 | 2023-06-09 | — | — | CN | claimed |
| CN-112778125-B | Aryl phenol compound and synthesis method and application thereof | 华东师范大学 | 2023-02-17 | — | — | CN | claimed |
| CN-115583922-A | Fluorine-containing N- (3- (benzoxazole-2-yl) phenyl) amide compound and preparation method and application thereof | 黄山学院 | 2023-01-10 | — | — | CN | claimed |
| US-11230526-B1 | Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-25 | — | — | US | claimed |
| CN-110476977-B | Application of 2- (1-adamantane carboxamide) ethyl formate compound as bactericide | 浙江工业大学 | 2021-08-10 | — | — | CN | claimed |
| CN-112778125-A | Aryl phenol compound and synthesis method and application thereof | 华东师范大学 | 2021-05-11 | — | — | CN | claimed |
| CN-110423216-B | 2- (1-adamantane carboxamide) ethyl formate compound and preparation method and application thereof | 浙江工业大学 | 2021-01-05 | — | — | CN | claimed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | claimed |
| WO-2001027118-A2 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | claimed |
| US-6184387-B1 | 2-(1,2-benzisothiazol-3(2H)-ylidene 1,1-dioxide)acetamides negative charge control agents for electrostatographic toners and developers | EASTMAN KODAK COMPANY | 2001-02-06 | — | — | US | claimed |
| WO-2001002375-A1 | PROCESS FOR SYNTHESIZING OXADIAZOLES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-01-11 | — | — | WO | claimed |
| US-6120964-A | TONERS WITH BINDERS | EASTMAN KODAK COMPANY (US) | 2000-09-19 | — | — | US | claimed |
| WO-1999011633-A1 | TRIAZINES WITH AN ADENOSINE ANTAGONISTIC EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-03-11 | — | — | WO | claimed |
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | claimed |
| US-4716168-A | STIMULANTS OF IMMUNE RESPONSE | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1987-12-29 | — | — | US | claimed |
| EP-0236874-A2 | Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes | BAYER AG (DE) | 1987-09-16 | — | — | EP | claimed |
| EP-0187705-A2 | Imidazo(4,5-f)quinolines useful as immunomodulating agents | Norwich Eaton Pharmaceuticals, Inc. (US) | 1986-07-16 | — | — | EP | claimed |
| EP-0065197-A1 | Substituted 1,3-dioxanes, process for their preparation, herbicides containing them and their use as herbicides | BASF Aktiengesellschaft (DE) | 1982-11-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230526-B1 | Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors | GPR119, GPR65, GPR55 | HSD17B10 430/4885TSHR 645/4885CYP3A4 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.